c-LEcta Accelerates Distribution of DENARASE® and Signs Sales Agreement With VWR
c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, strengthens the product marketing of its patented nuclease enzyme DENARASE ® through a sales cooperation with VWR, a global trading company for laboratory supplies. DENARASE ® offers more efficient production processes for biopharmaceuticals and has market potential in the double-digit million-euro range.
To continue its growth strategy, c-LEcta is further expanding its track record in the commercialization of its products. In addition to the recent successes in the food sector, the company is now pushing the accelerated product marketing in the pharma industry. The German industrial biotechnology expert has signed an agreement with VWR, an international laboratory supplies trading company, to sell its DENARASE® product. The product, which was mainly marketed by c-LEcta itself, will make a significant contribution to the company's sales in the current fiscal year 2018. Through the cooperation with VWR, c-LEcta is now addressing customers in the life science sector in an even more targeted manner. VWR is an important source of raw materials for these customers.
DENARASE® is a nuclease enzyme. It helps to remove genetic information carriers (nucleic acids; DNA and RNA) from the production process of biopharmaceuticals. The complete removal of nucleic acids from biopharmaceutical products is necessary to meet the high regulatory requirements for these products. The production process of the enzyme is patented. DENARASE® is currently the most efficient technology on the market for removing nucleic acids. This considerably simplifies the production process, reduces follow-up costs to a competitive level and ensures reliable availability. The manufacturing process meets the highest quality requirements of cGMP (current Good Manufacturing Practice) and thus meets the high demands of pharmaceutical manufacturers.
In the pharmaceutical industry, DENARASE® is used in multiple areas. A large share currently falls on the established vaccine market. Here c-LEcta is already active as a supplier for pharmaceutical companies. Another field for DENARASE® is the development and fabrication of components for use in cell and gene therapy. According to estimates by c-LEcta, the marketing of DENARASE® has a worldwide market potential in the double-digit million-euro range.
CEO Marc Struhalla: "With DENARASE®, we enable higher efficiencies in production processes than in conventional approaches and also set new standards in quality. In terms of price/performance ratio, we are thus offering the pharmaceutical industry a very attractive offer for optimizing their manufacturing procedures. The combination of our product innovation and VWR's access to the life science sector gives us the best prerequisites for gaining additional market share in a very dynamic market. We expect additional sales in the millions as an important contribution to our strong growth."
About c-LEcta
c-LEcta is a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry partners. The company currently employs approximately 60 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005155/en/
Contact information
cometis AG for c-LEcta
Maximilian Franz
Phone: +49 (0)
611 - 205855 – 22
Fax: +49 (0) 611 - 205855 – 66
E-mail: franz@cometis.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Xsolla Integrates MVola as a Payment Method to Enable Instant, Card-Free Payments for Gamers in Madagascar’s Mobile-First Market4.12.2025 22:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that MVola, Madagascar’s number one digital wallet, is now available as a payment option for players across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204268075/en/ Chris Hewish, President of Xsolla Madagascar is a fast-growing, mobile-first market of 32 million people, where digital wallets are the primary driver of daily transactions. MVola, recently licensed as a digital bank, has established itself as the leading wallet in the country, with over 10 million users and powering more than 1 billion transactions annually. By adding MVola as a payment method to its portfolio, Xsolla removes the friction of card payments, enabling players to pay seamlessly with a trusted local method they already know and use every day. Key benefits of the MVola integration include: Instant confirmations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom